Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL), of BPI Labs, LLC, NDA 205029. This launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.

According to IQVIATM sales data for the 12-month period ending December 2024, the Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) market2 achieved annual sales of approximately $42.7 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1313.35 as compared to the previous close of Rs. 1316.30. The total number of shares traded during the day was 4296 in over 664 trades.

The stock hit an intraday high of Rs. 1317.85 and intraday low of 1293.00. The net turnover during the day was Rs. 5613472.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USA EpinephrineInjection